Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Peripheral Arterial Disease | Treatment Algorithms | Claims Data Analysis | US | 2018
Treatment of peripheral arterial disease (PAD) has not changed significantly in recent years, and the typically prescribed drug classes for the prevention of atherothrombotic events are awash with…
Biosimilars | Emerging Biosimilars | Immunology | Inflectra/Renflexis | Wave 3 | US | 2018
Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (…
Ankylosing Spondylitis | Treatment Algorithms | Claims Data Analysis | US | 2018
AS is a chronic inflammatory disease belonging to the group of spondyloarthritides, involving primarily the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness…
Chronic Obstructive Pulmonary Disease | Treatment Algorithms | Claims Data Analysis | US | 2018
MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are beginning to gain traction in the COPD market, and both LAMAs and…
Biosimilars | Emerging Biosimilars | Truxima/Rixathon Launch Tracker | Germany | Wave 2 | 2018
Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a…
Breast Cancer | Access and Reimbursement |The influence of value assessment models on clinical pathways | US | 2017
Facing a dramatic rise in expenditures for cancer therapies, U.S. healthcare payers are increasingly assessing the value of drugs relative to their prices, taking into account attributes such as…
